small molecule

FEXINIDAZOLE

FEXINIDAZOLE

Loss of exclusivityJuly 2028FDA regulatory exclusivity expiry
CompanySANOFI AVENTIS US LLC

Drug detail

Brand nameFEXINIDAZOLE
Active ingredientFEXINIDAZOLE
Strength600MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2021
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-359July 2028
NCEJuly 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.